Scarica l'app Stockscreener
2.01
11.67%
0.21
Dopo l'orario di chiusura:
2.00
-0.010
-0.50%
Precedente Chiudi:
$1.80
Aprire:
$1.89
Volume 24 ore:
816.98K
Relative Volume:
2.09
Capitalizzazione di mercato:
$284.23M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-5.19%
1M Prestazione:
-13.36%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$1.86
$2.28
Intervallo di 1 settimana:
$1.78
$2.30
Portata 52W:
$1.70
$26.01
Veraxa Biotech Ag Stock (VRXA) Company Profile
Nome
Veraxa Biotech Ag
Settore
Industria
Telefono
-
Indirizzo
-
Compare VRXA vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRXA
Veraxa Biotech Ag
|
2.01 | 254.53M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Veraxa Biotech Ag Borsa (VRXA) Ultime notizie
Veraxa Biotech (VRXA) moves bispecific ADC VXA-222 program forward - Stock Titan
VERAXA Biotech (VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - NewMediaWire
VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - Benzinga
Veraxa Advances Bispecific ADC Candidate VXA-222 Following OmniAb Discovery Milestone - BioPharm International
VERAXA Biotech Advances Bispecific ADC Program VXA-222 Under OmniAb Collaboration - citybuzz -
VERAXA Biotech Shareholders Overwhelmingly Approve Corporate Governance and Financing Measures - citybuzz -
Veraxa Biotech AG Ord Shs (VRXA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Veraxa Biotech advances bispecific ADC from Omniab collaboration - BioWorld News
VERAXA Biotech Announces Advancement of VXA-222 Bispecific ADC Program in Collaboration with OmniAb - Quiver Quantitative
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb - NTB Kommunikasjon
Veraxa Biotech AG Ord Shs (VRXA) Balance Sheet - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
VRXA|Veraxa Biotech AG Ord Shs|Price:1.800|Chg%:-0.060 - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Veraxa Biotech shareholders approve governance changes By Investing.com - Investing.com India
VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer - USA Today
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth - The Manila Times
VERAXA Biotech AG (VRXA) Appoints Christoph Erkel as Chief Scientific Officer - NewMediaWire
Veraxa Biotech AG Revenue Breakdown – FWB:J8L0 - TradingView
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer, Bolstering Solid Tumor Pipeline - citybuzz -
VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel As Chief Scientific Officer - Menafn
VERAXA Biotech (VRXA) Advances BiTAC(R)-TCE Development With Positive Regulatory Feedback From Germany - Yahoo Finance
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Lead BiTAC Platform Development - citybuzz -
Veraxa Biotech names Christoph Erkel as chief scientific officer By Investing.com - Investing.com UK
VERAXA Biotech AG Appoints Christoph Erkel, Ph.D., as Chief Scientific Officer - Quiver Quantitative
VERAXA Taps 20-Year Antibody Expert to Guide New Cancer Treatments - Stock Titan
VERAXA Biotech Receives Positive Regulatory Guidance for BiTAC-TCE Platform from German Authority - citybuzz -
VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program - USA Today
symbol__ Stock Quote Price and Forecast - CNN
VERAXA Biotech Receives Regulatory Clarity on BiTAC-TCE Cancer Therapy Platform - citybuzz -
Veraxa Biotech AG Announces Regulatory Progress with Its BiTAC -TCE Development Plan - marketscreener.com
VERAXA Biotech (VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform - NewMediaWire
VERAXA Biotech (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform - TradingView
VERAXA Biotech Receives Positive Scientific Advice from Germany's PEI for its BiTAC®-TCE Program - citybiz
Veraxa Biotech receives feedback on BiTAC-TCE program - BioWorld News
VERAXA Biotech AG Receives Scientific Advice from Germany’s PEI on BiTAC-TCE Development Program - Quiver Quantitative
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan - The Manila Times
VERAXA cancer candidate targets two markers while sparing others - Stock Titan
Veraxa Biotech receives PEI scientific advice on BiTAC-TCE development plan - Bitget
VERAXA Biotech (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention - USA Today
Why VERAXA Biotech (VRXA) Could Benefit More Than Others From AI's Growing Impact on Drug R&D - Yahoo Finance
Why VERAXA Biotech (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D - Benzinga
VERAXA Biotech Leverages AI Partnership to Advance Cancer Therapy Platform - citybuzz -
VERAXA Biotech Appoints Carl von Halem as Interim CFO Amid Permanent Candidate Search - citybuzz -
VERAXA Biotech (VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development - NewMediaWire
VERAXA Biotech Partners with Ardigen to Integrate AI in Cancer Drug Development - citybuzz -
VERAXA Biotech (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development - Benzinga
Veraxa partners with Ardigen on AI-driven cancer target selection - Investing.com UK
Veraxa Biotech Ag Azioni (VRXA) Dati Finanziari
Non sono disponibili dati finanziari per Veraxa Biotech Ag (VRXA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):